Evaluation of lymphocyte apoptosis in dogs with inflammatory bowel disease

Dandrieux, Julien; Bornand, V.; Doherr, Marcus G.; Kano, Rui; Zurbriggen, Andreas; Burgener, Iwan

doi:10.2460/ajvr.69.10.1279

Cited by 27 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28,29 Calprotectin induces cell death by modulation of the balance between anti-and proapoptotic Bcl-2 toward the expression of proapoptotic Bcl-2, 29 which increases in dogs with idiopathic IBD after treatment and has been suggested as a potential biomarker for treatment success. 30 In the study reported here, the reason serum calprotectin concentration increased by a greater magnitude in dogs that were treated with a combination of prednisone and metronidazole than in dogs that were treated with prednisone alone is difficult to explain. Metronidazole inhibits neutrophil function 31 and proinflammatory cytokine production by monocytes and macrophages but does not affect the anti-inflammatory cytokines IL-4 and IL-10.…”

Section: Discussionmentioning

confidence: 82%

Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease

Heilmann

Jergens²,

Ackermann³

et al. 2012

ajvr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease

Heilmann

Jergens²,

Ackermann³

et al. 2012

ajvr

View full text Add to dashboard Cite

show abstract

“…Genomic biomarkers include single nucleotide polymorphisms (SNPs) in TLR4 , TLR5 , nucleotide oligomerization domain (NOD)2 , and the neutrophil cytosolic factor (NCF2) gene,153, 154, 155, 156, 157, 158, 159, 160, 161 a reduction of genetic diversity (eg, T cell receptor repertoire),162 and also alterations in the expression of several other genes (eg, genes encoding TLR2, TLR4, TLR5, TLR9, caspase‐3, and B‐cell lymphoma [Bcl]‐2) 115, 163, 164, 165, 166. Overexpression of some marker genes also was associated with clinical disease severity 164, 165, 166.…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

“…14,39,43,54,59 Differentiation of IBD from EATL type 2 may be further complicated by the potential transformation of IBD to lymphoma, as suggested by some. 12,24,28 Other less common intestinal lymphomas in cats include EATL type 1, a large cell lymphoma, or B-cell lymphomas, either diffuse large B-cell lymphomas or mucosaassociated lymphoid tissue lymphomas. Similar to cats, a predominance of intestinal T-cell lymphomas has also been reported in dogs, 21,38,40,44 which is in contrast to canine multicentric lymphomas as well as human gastrointestinal lymphomas that are more commonly of B-cell origin.…”

mentioning

confidence: 99%

Distinguishing Intestinal Lymphoma From Inflammatory Bowel Disease in Canine Duodenal Endoscopic Biopsy Samples

et al. 2014

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) and intestinal lymphoma are intestinal disorders in dogs, both causing similar chronic digestive signs, although with a different prognosis and different treatment requirements. Differentiation between these 2 conditions is based on histopathologic evaluation of intestinal biopsies. However, an accurate diagnosis is often difficult based on histology alone, especially when only endoscopic biopsies are available to differentiate IBD from enteropathy-associated T-cell lymphoma (EATL) type 2, a small cell lymphoma. The purpose of this study was to evaluate the utility of histopathology; immunohistochemistry (IHC) for CD3, CD20, and Ki-67; and polymerase chain reaction (PCR) for antigen receptor rearrangement (T-cell clonality) in the differential diagnosis of severe IBD vs intestinal lymphoma. Endoscopic biopsies from 32 dogs with severe IBD or intestinal lymphoma were evaluated. The original diagnosis was based on microscopic examination of hematoxylin and eosin (HE)-stained sections alone followed by a second evaluation using morphology in association with IHC for CD3 and CD20 and a third evaluation using PCR for clonality. Our results show that, in contrast to feline intestinal lymphomas, 6 of 8 canine small intestinal lymphomas were EATL type 1 (large cell) lymphomas. EATL type 2 was uncommon. Regardless, in dogs, intraepithelial lymphocytes were not an important diagnostic feature to differentiate IBD from EATL as confirmed by PCR. EATL type 1 had a significantly higher Ki-67 index than did EATL type 2 or IBD cases. Based on the results of this study, a stepwise diagnostic approach using histology as the first step, followed by immunophenotyping and determining the Ki67 index and finally PCR for clonality, improves the accuracy of distinguishing intestinal lymphoma from IBD in dogs.

show abstract

Evaluation of lymphocyte apoptosis in dogs with inflammatory bowel disease

Cited by 27 publications

References 29 publications

Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease

Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Distinguishing Intestinal Lymphoma From Inflammatory Bowel Disease in Canine Duodenal Endoscopic Biopsy Samples

Contact Info

Product

Resources

About